Showing 15 posts of 222 posts found.

FDA approves first endometriosis pain management drug in a decade

July 25, 2018
Research and Development, Sales and Marketing AbbVie, FDA, Neurocrine Biosciences, endometriosis, pharma

The FDA has confirmed its approval of AbbVie and Neurocrine Biosciences’ Orilissa (elagolix), a nonpeptide small molecule gonadotropin-releasing hormone (GnRH) …


AbbVie and Mylan reach US marketing agreement for Humira biosimilar

July 18, 2018
Research and Development, Sales and Marketing AbbVie, Humira, Mylan, US, pharma

AbbVie and Mylan have announced that they have both signed a licensing agreement for the former’s proposed biosimilar version of …

AbbVie and Janssen announce failure of cancer drug Imbruvica in Phase 3 trial

July 12, 2018
Research and Development AbbVie, Cancer, FDA, Janssen, approval

AbbVie and Janssen have announced that Imbruvica (ibrutinib) failed to achieve the primary endpoint in a late-stage study assessing its …


Syntimmune appoints Pfizer, AbbVie veteran as new CMO

July 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, CMO, John Hopkins University, Pfizer, Syntimmune

The Boston-based clinical biotechnology company Syntimmune has appointed Dr Mario Saltarelli as its Chief Medical Officer. Dr Saltarelli will take …


AbbVie ordered to pay $448m over generic delays

July 2, 2018
Sales and Marketing AbbVie, FTC, androgel, besins, branded generics, pharma

A US Judge has ordered pharmaceutical company AbbVie to pay $448 million after determining that the company had used sham …


Abbvie and Google’s Calico extend age-related disease partnership to $2.5bn

June 27, 2018
Research and Development, Sales and Marketing AbbVie, Cancer, Goggle, calico, pharma

The partnership of Abbvie and Google’s Calico has announced they are to extend their existing 10-year drug discovery and development …


AbbVie/Roche gain FDA approval for blockbuster treatment

June 11, 2018
Sales and Marketing AbbVie, Roche, biotech, drugs, pharma, pharmaceutical

AbbVie and Roche have a chalked up a major success, after the FDA gave its approval for Venclexta, in combination …


New hepatitis C combo boasts 97% cure rate for just $300

April 12, 2018
Research and Development AbbVie, DNDi, Drugs for Neglected Diseases initiative, Gilead, HCV, Pharco Pharmaceuticals, hepatitis C, pharma, sovaldi

A partnership of the not-for-profit organisation Drugs for Neglected Diseases initiative (DNDi) and Egyptian drug firm Pharco Pharmaceuticals is working …


AbbVie’s rheumatoid arthritis drug bests even its own blockbuster Humira at Phase 3

April 11, 2018
Research and Development AbbVie, Humira, pharma, rheumatoid arthritis, upadacitinib

AbbVie posted a strong showing this week from its JAK1 inhibitor upadacitinib, indicating that the drug outperformed even its own …


Samsung Bioepis and Biogen secure licensing deal with Abbvie for Humira biosimilar

April 6, 2018
Medical Communications, Sales and Marketing AbbVie, Biogen, Humira, Imraldi, Samsung Bioepis, biosimilar, pharma

Partners Biogen and Samsung Bioepis have secured the future of their Humira (adalimumab) biosimilar after penning a deal with Abbvie …


Abbvie pays out over $3m after its testosterone replacement drug leads to heart attack

March 27, 2018
Manufacturing and Production, Sales and Marketing AbbVie, Endo, GSK, androgel, heart attack, pharma

Abbvie has been ordered to pay over $3 million in damages to a man who asserts that the uise of …


Ablynx’s vobarilizumab trial fails and sees two patient deaths in systemic lupus erythematosus

March 26, 2018
Research and Development, Sales and Marketing AbbVie, Ablynx, Sanofi, Vobarilizumab, pharma, systemic lupus erythematosus

Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint …


AbbVie secures further strong results for potential blockbuster

March 13, 2018
Research and Development AbbVie, biotech, drugs, elagolix, pharma, pharmaceutical

AbbVie’s elagolix has been slated as a blockbuster-in-the-making by analysts predicting big things for the potential treatment for uterine fibroids …

Latest content